Aptamer Group raises £60,000 via Supplementary Conditional Placing

Aptamer Group

Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has announced that, in addition to the Placing and Subscription announced on 24 July 2024, it has agreed to issue a further 30,000,000 New Ordinary Shares at the same issue price of 0.2p per share, raising £60,000 (before expenses), which will be for working capital purposes.

This additional sum has arisen due to a reconciliation error by the Company’s broker, Turner Pope Investments (TPI) Ltd, relating to client orders received in the Fundraising. Turner Pope noticed this matter yesterday and informed the Company and the Board has agreed to issue the Supplementary Placing Shares.

Notwithstanding the circumstances under which the proposed issue of the Supplementary Placing Shares has arisen, they will not form part of the Fundraising and will be issued as a separate tranche. Both the conditional element of the Fundraising and the Supplementary Placing Shares are subject to shareholder approval of the resolutions at the Company’s General Meeting, which is scheduled for 13 August 2024.

Subject to the passing of the resolutions at the General Meeting, admission of the Supplementary Placing Shares is expected to become effective and dealings are expected to commence at 8.00 a.m. on 14 August 2024.

Total Voting Rights

Immediately following Admission the Company will have 1,920,343,673 ordinary shares of £0.001 each in issue.

Aptamer Group does not hold any shares in treasury and all of the Ordinary Shares have equal voting rights. Therefore, the figures above represent the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in the Company under the Rules.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:

Latest Company News

Aptamer Group AGM statement highlights contract wins and growing order book

Aptamer Group is holding its AGM today in York, where the Chairman will outline continued commercial progress, recent contract wins with major pharmaceutical companies, and an FY26 order book of £1.95 million.

Aptamer Group secures £192k contracts with global pharma, boosting FY26 order book to £1.95m

Aptamer Group announced two new contracts worth £192,000, including a fourth engagement with a top five global pharmaceutical company and a new deal targeting acute myeloid leukaemia.

Aptamer Group reports strong FY2025 growth and expands Optimer® portfolio

Aptamer Group delivered strong progress in FY2025, achieving a 40% revenue increase and expanding its portfolio of licensable Optimer® assets from four to eleven.

Aptamer Group delivers 40% revenue growth and expands licensing portfolio

Aptamer Group has announced its full-year results for the twelve months ended 30 June 2025, delivering a 40% increase in revenue to £1.2 million and expanding its Optimer® licensing portfolio from four to eleven assets.

Aptamer Group secures repeat contract for Optimer® binder development

Aptamer Group has signed a new agreement with an existing partner to develop Optimer® binders targeting two proteins for biomarker research.

Aptamer Group to announce full year 2025 results on 14 October

Aptamer Group will publish results for the year ended 30 June 2025 on Tuesday, 14 October 2025, with an online analyst briefing at 9.30 am hosted by CEO Dr Arron Tolley and CFO Andrew Rapson. .

    Search

    Search